Table 1 Characteristics of outpatient cases (n = 302,782)
|
GP (n = 110,352) |
ENT specialist (n = 119,170) |
Pediatrician (n = 28,986) |
Other specialist (n = 20,298) |
Total (n = 302,782) | |
|---|---|---|---|---|---|
| Median age, years (IQR) | 52 (21–74) | 49 (17–72) | 7 (4–11) | 58 (23–75) | 46 (16–72) |
| Sex | |||||
| Male | 59,723 (54.1%) | 66,618 (55.9%) | 16,957 (58.5%) | 10,338 (50.9%) | 166,877 (55.1%) |
| Female | 50,629 (45.9%) | 52,552 (44.1%) | 12,029 (41.5%) | 9960 (49.1%) | 135,905 (44.9%) |
| Comorbidities/ antithrombotic medicationa | |||||
| Arterial hypertension (I10-I15) | 50,642 (45.9%) | 47,118 (39.5%) | 369 (1.3%) | 9960 (49.1%) | 120,702 (39.9%) |
| Chron. ischemic heart disease/ Coronary heart disease (I25) | 17,789 (16.1%) | 17,305 (14.5%) | 38 (0.1%) | 3797 (18.7%) | 43,970 (14.5%) |
| Atrial fibrillation/flutter (I48) | 11,704 (10.6%) | 10,667 (9.0%) | 23 (0.1%) | 2557 (12.6%) | 28,857 (9.5%) |
| Antithrombotics | 20,417 (18.5%) | 19,855 (16.7%) | 62 (0.2%) | 4538 (22.4%) | 51,508 (17.0%) |
| Co-diagnosed diseasesb | |||||
| Acute | |||||
| Respirator. inf. (B34.9, J06, J98.7) | 10,410 (9.4%) | 2898 (2.4%) | 8847 (30.5%) | 1452 (7.2%) | 24,000 (7.9%) |
| Acute rhinitis (J00) | 1999 (1.8%) | 2729 (2.3%) | 1580 (5.5%) | 347 (1.7%) | 6751 (2.2%) |
| Acute bronchitis (J20) | 4445 (4.0%) | 187 (0.2%) | 2543 (8.8%) | 729 (3.6%) | 7949 (2.6%) |
| Hypertensive urgencies (I10.91) | 2072 (1.9%) | 111 (0.1%) | 6 (0.0%) | 293 (1.4%) | 3171 (1.1%) |
| Chronic | |||||
| Chron. rhinitis (J31.0) | 3555 (3.2%) | 26,301 (22.1%) | 1678 (5.8%) | 533 (2.6%) | 32,127 (10.6%) |
| Chron. sinusitis (J32) | 3176 (2.9%) | 6391 (5.4%) | 329 (1.1%) | 450 (2.2%) | 10,377 (3.4%) |
| Chron. bronchitis/ COPD (J44) | 8642 (7.8%) | 355 (0.3%) | 374 (1.3%) | 1309 (6.5%) | 10,703 (3.5%) |
| Traumatic | |||||
| Nasal bone fracture (S02.2) | 237 (0.2%) | 478 (0.4%) | 11 (0.0%) | 63 (0.3%) | 1046 (0.4%) |
| Nasal bone contusion (S00.3) | 475 (0.4%) | 365 (0.3%) | 327 (1.1%) | 82 (0.4%) | 1749 (0.6%) |
| Foreign body, nose (T17.0, T17.1) | 18 (0.0%) | 662 (0.6%) | 11 (0.0%) | 11 (0.1%) | 711 (0.2%) |
| Acquired deformity of the nose (M95.0) | 9 (0.0%) | 7011 (5.9%) | 1 (0.0%) | 128 (0.6%) | 7.155 (2.4%) |
| Neoplastic | |||||
| Malignant tumor of the nasopharynx, nasal (adjacent) cavity (C11, C30, C31) | 45 (0.0%) | 101 (0.1%) | 0 (0.0%) | 6 (0.0%) | 154 (0.1%) |
| Myelodysplastic syndrome (D46) | 185 (0.2%) | 9 (0.0%) | 0 (0.0%) | 58 (0.3%) | 258 (0.1%) |
| Hematological | |||||
| Thrombocytopenia (D69.4–.6) | 870 (0.8%) | 125 (0.1%) | 32 (0.1%) | 186 (0.9%) | 1235 (0.4%) |
| Hemophilia A and B (D66, D67) | 99 (0.1%) | 17 (0.0%) | 20 (0.1%) | 9 (0.0%) | 151 (0.1%) |
| Willebrand-Jürgens Sy.(D68.0) | 186 (0.2%) | 83 (0.1%) | 112 (0.4%) | 105 (0.5%) | 501 (0.2%) |
| Hereditary hemorrhagic telangiectasia (I78.0) | 391 (0.4%) | 268 (0.2%) | 1 (0.0%) | 67 (0.3%) | 756 (0.3%) |
| Cirrhosis of the liver (K74) | 717 (0.7%) | 66 (0.1%) | 4 (0.0%) | 97 (0.5%) | 892 (0.3%) |
| Liver failure (K70, K72) | 700 (0.6%) | 16 (0.0%) | 1 (0.0%) | 135 (0.7%) | 854 (0.3%) |
| Structural | |||||
| Nasal septum deviation (J34.2) | 1203 (1.1%) | 12,357 (10.4%) | 24 (0.1%) | 243 (1.2%) | 13,856 (4.6%) |
| M. Osler (I78) | 481 (0.4%) | 1514 (1.3%) | 16 (0.1%) | 95 (0.5%) | 2135 (0.7%) |
| Sicca Syndrome (M35.0) | 210 (0.2%) | 46 (0.0%) | 0 (0.0%) | 19 (0.1%) | 275 (0.1%) |
| Medications /Noxae | |||||
| Drug abuse (F55) | 72 (0.1%) | 56 (0.1%) | 1 (0.0%) | 10 (0.1%) | 148 (0.1%) |
| Cocaine abuse (F14) | 4 (0.0%) | 1 (0.0%) | 0 (0.0%) | 11 (0.1%) | 16 (0.0%) |
| Alcohol addiction (F10) | 2297 (2.1%) | 80 (0.1%) | 1 (0.0%) | 340 (1.7%) | 2796 (0.9%) |
| Inflammatory | |||||
| Allergy (T78.4) | 3502 (3.2%) | 1136 (1.0%) | 1064 (3.7%) | 706 (3.5%) | 6416 (2.1%) |
| Allergic rhinitis (J30) | 5033 (4.6%) | 7230 (6.1%) | 2241 (7.7%) | 712 (3.5%) | 15,239 (5.0%) |
| No other diagnosis | 9581 (8.7%) | 33,493 (28.1%) | 2928 (10.1%) | 2799 (13.8%) | 66,060 (21.8%) |
| Median number of co-diagnosed diseases (IQR)b/c | 5 (2–12) | 1 (0–3) | 3 (1–5) | 5 (2–11) | 2 (1–6) |